Emyria (ASX: EMD) — Company Overview, News & Financial Data
Emyria is a clinical-stage healthcare and biopharmaceutical company focused on developing novel therapies and delivering clinical care for mental health conditions and chronic pain.
Emyria
Emyria is a clinical-stage healthcare and biopharmaceutical company focused on developing novel therapies and delivering clinical care for mental health conditions and chronic pain. The company integrates specialized clinical practice with proprietary drug development, operating clinical care centers that provide MDMA-assisted psychotherapy and ketamine treatments for treatment-resistant conditions. Emyria leverages anonymized real-world data collected from its clinics to inform clinical protocols and accelerate regulatory pathways for its pipeline of synthetic cannabinoid formulations and novel psychedelic analogs. Through partnerships with research institutions, the company aims to address significant unmet medical needs in neuro-psychiatric healthcare across Australia.
Snapshot
Products and/or services of Emyria
- Clinical Care Networks: Emyria operates specialized medical clinics across Australia providing clinical care for patients suffering from treatment-resistant mental health conditions, severe chronic pain, and complex neurological disorders through evidence-based therapies.
- MDMA-Assisted Therapy Services: The company delivers structured MDMA-assisted psychotherapy protocols for post-traumatic stress disorder within authorized clinical environments, utilizing trained psychiatrists and multidisciplinary care teams to deliver long-term patient outcomes.
- Proprietary Cannabinoid Formulations: Emyria advances clinical-stage synthetic cannabinoid drug candidates including EMD-RX5 and EMD-RX7, designed for oral administration to treat specific neurological and psychological conditions through formal regulatory approval pathways.
- Real-World Data Platform: The company leverages proprietary clinical data collection systems across its clinic network to gather real-world evidence on treatment efficacy and safety, supporting internal drug development and regulatory submissions.
- Novel Psychedelic Analogs R&D: Emyria conducts preclinical research and pipeline development on novel MDMA analogs created in collaboration with academic research partners to target specific neuro-psychiatric conditions with improved therapeutic profiles.
- Ketamine-Assisted Psychotherapy: The company provides authorized ketamine-assisted therapy protocols within its clinical network for patients with severe depression and treatment-resistant psychiatric conditions, integrating specialized medical monitoring with clinical psychotherapy support.
Emyria executive team
- Gregory HutchinsonExecutive Chairman
- Michael WinloChief Scientific Officer & Executive Director
- Joseph Daniel OhayonChief Financial Officer
- Alistair VickeryExecutive Medical Director & Director
- Mary-Ann RennieHead of Corporate Operations
Recent announcements
What Emyria (EMD) has told the market, newest first.
- Annual Report
- Appendix 4G and Corporate Governance Statement
- Letter to Shareholders - Notice of Annual General Meeting
- Notice of Annual General Meeting/Proxy Form
- Retirement of Non-Executive Director
- Webinar with Former Secretary of Veterans Affairs Dr Shulkin
- Notification of cessation of securities - EMD
- Emyria Confirms NSW Workforce Ahead of Clinic OpeningPrice sensitive
Key financials
Reported results for Emyria, in AUD.
- Market cap
- 31.5M
- Revenue (TTM)
- 4.1M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- -150.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 3.9M | -6.3M | -6.1M | |
| 1.4M | -2.6M | -3.1M | |
| 2.2M | -6.9M | -11.5M | |
| 1.6M | -7.1M | -5.1M |